Janone to present prior phase ii data on diabetic neuropathy at the ohio society of interventional pain physicians annual meeting

Jan101 showed statistically significant reduction in pain and improvement in nerve conduction velocity in prior phase ii study. las vegas , aug. 18, 2023 /prnewswire/ -- janone (nasdaq: jan), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present prior data on jan101's randomized double blind placebo-controlled trial in diabetic neuropathy patients.
JAN Ratings Summary
JAN Quant Ranking